Cannabidiol

大麻二酚

Report date: 2026/05/28 20:00:21
NMEQIDP

Base Information

Drug NameCannabidiol
Drug Alias Namecannabidiolum大麻双酚Cannabis大麻二酮酚CBD +[25] 
ClassificationSmall molecules
Mechanisms of ActionCannabinoid CB2 receptor inverse agonistsCannabinoid CB1 receptor inverse agonistsSerotonin 5-HT1 receptors modulators +[4] 
TargetsCannabinoid CB1 receptorCannabinoid CB2 receptorSerotonin 5-HT1 receptors +[4] 
Therapy Area/IndicationsSedationCoronavirus Disease 2019 (COVID-19)Muscle injury +[146] 
Global Approved IndicationsLennox Gastaut SyndromeEpilepsies, Myoclonic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/06/25
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGw Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesCentre Integre Universitaire De Sante Et Services Sociaux Du Nord De L'Ile De MontrealUtah State UniversityDana-Farber Cancer Institute +[74] 
Inactive CompaniesPure GreenKnop LaboratoriosColorado State University +[27] 
Active IndicationsSedationMuscle injuryPrurigo Nodularis +[107] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders +[39] 

Other Information

ATC CodeN03AX24
Related LinksWikipediaDrugBankKEGG